½ÃÀ庸°í¼
»óÇ°ÄÚµå
1444107
¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)Multi-Parameter Patient Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) |
¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð´Â 2024³â 114¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 7.48%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2029³â±îÁö 164¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COVID-19´Â ½ÉÀå ¹× ½Å°æ°è ÇÕº´ÁõÀ» Æ÷ÇÔÇÑ ¿©·¯ µ¿¹Ý ÁúȯÀ» ¾Î°í ÀÖ´Â COVID-19 ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ãʱ⠴ܰ迡¼ ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃƽÀ´Ï´Ù. ¿¹¸¦ µé¾î, PubMed°¡ 2022³â 3¿ù¿¡ ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, COVID-19 °¨¿°ÁõÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ÀÇ·á ¼ºñ½º È¥ÀâÀ» ¿ÏÈÇϱâ À§ÇØ Ä³³ª´Ù¿¡¼ ȯÀÚ ¸ð´ÏÅ͸µÀÌ Å©°Ô Áõ°¡Çß´Ù´Â ¿¬±¸ °á°ú°¡ ¹ßÇ¥µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ 2021³â 3¿ù PubMed¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é, ¿¬±¸ÁøÀº ÆÒµ¥¹Í ±â°£ µ¿¾È ÀÎÅÍ³Ý ÀÎÇÁ¶ó¸¦ È°¿ëÇÑ È°·Â¡ÈÄ ¿ø°ÝÀÇ·á ½Ã½ºÅÛÀ» °³¹ßÇß´Ù°í ÇÕ´Ï´Ù. µû¶ó¼ ¿ø°Ý ÀÇ·á°¡ Á¦°øÇÏ´Â ÀÌÁ¡À¸·Î ÀÎÇØ ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µÀº ±×´ÙÁö ¹Ù»ÚÁö ¾Ê¾Ò½À´Ï´Ù. ÇöÀç ¸¸¼º ÁúȯÀÇ Áõ°¡, ÀÇ·á±â±â ¼öÃâÀÔ ±ÔÁ¦ ¿ÏÈ, ȯÀÚ ¸ð´ÏÅ͸µ ¹× ÀçÅà ±â±â ¼ö¿ä µîÀ¸·Î ÀÎÇØ ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. µû¶ó¼ ½ÃÀåÀº ¿¬±¸ ¿¹Ãø ±â°£ µ¿¾È ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ºÀåÀº ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È, ³ëÀÎ Àα¸ÀÇ Áõ°¡, ÀçÅà ¹× ¿ø°Ý ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ÈÞ´ë¿ë ±â±âÀÇ »ç¿ë ÆíÀǼºÀ¸·Î ÀÎÇÑ ¸¸¼º ÁúȯÀÇ ºÎ´ã Áõ°¡¿¡ ±âÀÎÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¿¹¸¦ µé¾î, IARCÀÇ ÃßÁ¤¿¡ µû¸£¸é 2025³â±îÁö 21,618,445¸íÀÇ »õ·Î¿î ¾Ï ȯÀÚ°¡ ¹ß»ýÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, 2030³â±îÁö 24,044,406¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¹Ì±¹½ÉÀåÇùȸÀÇ ½ÉÀå ¹× ³úÁ¹Áß Åë°è 2022 ÃÖ½ÅÆÇ¿¡ µû¸£¸é, EMS°¡ Æò°¡ÇÑ ¸ðµç ¿¬·É´ëÀÇ ºñ¿Ü»ó¼º º´¿ø¿Ü ½ÉÁ¤Áö(OHCA) ¹ß»ý·üÀº 356,461¸í, Áï ¸ÅÀÏ 1,000¸í¿¡ À°¹ÚÇÏ´Â °ÍÀ¸·Î Ãß»êµË´Ï´Ù. °°Àº º¸°í¼¿¡ µû¸£¸é ¹Ì±¹¿¡¼´Â ¸Å³â 356,000°Ç ÀÌ»óÀÇ º´¿ø¿Ü ½ÉÁ¤Áö(OHCA)°¡ ¹ß»ýÇϸç, ±× Áß °ÅÀÇ 90%°¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. µû¶ó¼ ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·üÀ» °í·ÁÇÒ ¶§ ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ÀåÄ¡¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
ȯÀÚ ¸ð´ÏÅ͸µ ±â¼úÀº ȯÀÚÀÇ »ý¸®Àû µ¥ÀÌÅÍÀÇ ÀÛÀº º¯È¸¦ ½Äº°ÇÏ°í ÀÚ°¡ ¸ð´ÏÅ͸µÀ» ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ±× °á°ú, ÀçÀÔ¿øÀ̳ª ºÒÇÊ¿äÇÑ ÀÔ¿øÀ» ÁÙÀÌ°í, ºÒÇÊ¿äÇÑ º´¿ø ¹æ¹® Ƚ¼ö¿Í ¿©Çà ºñ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ ¸ð´ÏÅ͸µ ±â¼úÀ» ¿Ã¹Ù¸£°Ô »ç¿ëÇÏ¸é ½Ã°£°ú ºñ¿ëÀ» Àý¾àÇÏ¸é¼ ¾çÁúÀÇ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¸¸¼º Áúȯ Ä¡·á ¿¬±¸ ¹× °³¹ß °ü·Ã Á¤ºÎ ÀÚ±Ý Áö¿ø°ú °°Àº ´Ù¸¥ ¿äÀε鵵 ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 11¿ù ij³ª´Ù Á¤ºÎÀÇ ÃֽŠÁ¤º¸¿¡ µû¸£¸é, 2021³â ij³ª´Ù´Â ´ç´¢º´¿¡ 3,500¸¸ ´Þ·¯¸¦ ÅõÀÚÇßÀ¸¸ç, ƯÈ÷ ´ç´¢º´ Á¶»ç, ¸ð´ÏÅ͸µ, ¿¹¹æ ¹× ´ç´¢º´ ±¹°¡ ÇÁ·¹ÀÓ¿öÅ© °³¹ß¿¡ 2,500¸¸ ´Þ·¯¸¦ ÅõÀÚÇß½À´Ï´Ù. ¿©±â¿¡´Â JDRF ij³ª´Ù¿Í ±âºÎÀÚ°¡ 1Çü ´ç´¢º´ Á¶»ç¿¡ ÃÖ´ë 1,500¸¸ ´Þ·¯¸¦ ÅõÀÚÇÏ¿© û¼Ò³â ´ç´¢º´ ¿¬±¸ Àç´Ü(JDRF)°ú ij³ª´Ù º¸°Ç Á¶»ç ±â°ü(CIHR)ÀÇ ´ç´¢º´ ÅðÄ¡ ÆÄÆ®³Ê½Ê¿¡ ´Ù½Ã ÇÑ ¹ø Çå½ÅÇÏ´Â °ÍÀÌ Æ÷ÇԵ˴ϴÙ.
µû¶ó¼, ¸¸¼º ÁúȯÀÇ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ö¿ä´Â Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ ¿öÅ©¿Í ÀûÀýÇÑ »óȯ ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ¹æÇØ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ÖƼ ÆĶó¹ÌÅÍ ¸ð´ÏÅÍ¿¡´Â ÈÞ´ë¿ë°ú °íÁ¤Çü µÎ °¡Áö ÁÖ¿ä À¯ÇüÀÌ ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ¸ð´ÏÅÍ´Â Ãë±ÞÀÇ ¿ëÀ̼º°ú ÆíÀǼºÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ÀçÅà ÀÇ·áÀÇ ¼ºÀå, ¼ö¼ú ÈÄ È¸º¹±â ȯÀÚ ¸ð´ÏÅ͸µÀÇ ¿ëÀ̼º, ¿Ü·¡ Ä¡·á ½Ã¼³ÀÇ Áõ°¡, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ Ã¤Åà Áõ°¡¿Í °°Àº ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 3¿ù ÆÄÅ°½ºÅº Àú³Î ¿Àºê »çÀ̾ð½º(Pakistan Journal of Science)¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, ÀÇ·á °á°ú¸¦ °³¼±ÇÏ°í ȯÀÚ Áß½É Ä¡·á¸¦ ½ÇÇöÇÏ´Â ÈÞ´ë¿ë ½º¸¶Æ® ¹Ì´Ï ȯÀÚ ¸ð´ÏÅÍ ÇÁ·ÎÅäŸÀÔÀº ½É¹Ú¼ö, ü¿Â, ½ÉÀüµµ, ½É¹Ú¼ö ¹× SPO2¿Í °°Àº Áß¿äÇÑ »ý¸®Àû ½ÅÈ£¸¦ Æ÷ÂøÇÏ°í Ç¥½ÃÇß½À´Ï´Ù. ÀÌ ¿¬±¸´Â ¿©·¯ ¼¾¼¸¦ ÇϳªÀÇ ÈÞ´ë¿ë ÀåÄ¡¿¡ °áÇÕÇÏ¿© Á¤È®ÇÑ Á¤È®µµ·Î ´Ù¾çÇÑ »ý¸®Àû ½ÅÈ£¸¦ ÇÑ ¹ø¿¡ »ý¼ºÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. »ç¶÷µéÀº ½±°Ô ±â·ÏÇÏ°í ÀúÀåÇÏ°í ÀÇ·á Áø´Ü¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
¶ÇÇÑ ±â¼ú ¹ßÀüÀÇ Áõ°¡·Î ÀÎÇØ ÁÖ¿ä ½ÃÀå ±â¾÷ °£ÀÇ °æÀïÀÌ Ä¡¿ÇØÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù ½Ì°¡Æ÷¸£ ºê·£µå BUZUDÀÎ Fosun Trade Medical Device´Â µÎ °¡Áö »õ·Î¿î ÀÇ·á±â±â¸¦ Ãâ½ÃÇß½À´Ï´Ù. BUZUD ¸ÖƼ ÆĶó¹ÌÅÍ ¸ð´ÏÅÍ(MPM)´Â ÀÇ·á ¸ð´ÏÅ͸µ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇÏ°í ÀÇ·á Á¾»çÀÚ°¡ ´õ ¸¹Àº ȯÀÚ Ä¡·á¸¦ Á¦°ø ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. µÎ ¹ø°´Â °³ÀÎ¿ë ½ÉÀüµµ(ECG) ÃßÀû±â BUZUD PulseBit EX·Î, ½ÉÀ庴 ȯÀÚÀÇ ½ÉÀå °ü¸®¸¦ Àú·ÅÇÏ°í Æí¸®ÇÏ°Ô ¸¸µé¾îÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Ãâ½Ã´Â ÀÌ ½ÃÀå ºÎ¹®ÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.
ÇコÄɾ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¼ö¼ú ÀüÈÄ È¯ÀÚÀÇ °Ç° ¸Å°³º¯¼ö¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â °Í¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÈÞ´ë¿ë ¸ÖƼ ÆĶó¹ÌÅÍ ¸ð´ÏÅÍ ½ÃÀåÀÇ ¼ºÀåÀÌ ÃËÁøµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì¿¡¼´Â ¿¹Ãø ±â°£ µ¿¾È Àüü ¸ÖƼ ÆĶó¹ÌÅÍ ¸ð´ÏÅ͸µ ½ÃÀåÀÌ ¼ºÀåÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ ¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀº °íÇ°Áú ÀÇ·á ½Ã½ºÅÛ°ú ÃֽŠÀÇ·á ±â¼ú·Î ÀÎÇØ ºÏ¹Ì Áö¿ª¿¡¼ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ Áõ°¡¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È°¡ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çß½À´Ï´Ù. ¿¹¸¦ µé¾î, ±¹Á¦´ç´¢º´¿¬¸Í(IDF)ÀÌ 2021³â ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, 2021³â ij³ª´ÙÀÇ ´ç´¢º´ À¯º´·ü(10¸¸ ¸í´ç)Àº 0-14¼¼ ¾Æµ¿ÀÇ ¾à 37.9%¿¡ ´ÞÇß½À´Ï´Ù. ¶ÇÇÑ 2021³â ij³ª´Ù¿¡¼ ´ç´¢º´À» ¾Î°í ÀÖ´Â 20-79¼¼ ¼ºÀÎÀÇ ¼ö´Â ¾à 300¸¸ ¸í¿¡ ´ÞÇß½À´Ï´Ù. µû¶ó¼ ij³ª´Ù¿¡¼ ´ç´¢º´ÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÖƼ ÆĶó¹ÌÅÍ ¸ð´ÏÅ͸µ ½ÃÀåÀº °ÇÀüÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¶ÇÇÑ, ÁÖ¿ä ±â¾÷µéÀº Áö¿ª ½ÃÀå¿¡¼ ´õ ³ôÀº ½ÃÀå Á¡À¯À²À» È®º¸Çϱâ À§ÇØ Àü·«Àû ³ë·ÂÀ» ±â¿ïÀÌ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 7¿ù ¾Öº¸Æ®´Â »ðÀÔÇü ½ÉÀå ¸ð´ÏÅÍÀÎ Jot Dx¸¦ Ãâ½ÃÇß½À´Ï´Ù. µ¥ÀÌÅÍ ºÎ´ãÀ» ÁÙÀÌ°í ºñÁ¤»óÀûÀÎ ½ÉÀå ¹Úµ¿ ¸®µëÀ» Áø´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù. 2021³â 2¿ù, ºñħ½ÀÀû Ç÷¿ªÇÐ ¸ð´ÏÅ͸µ¿¡ ÁßÁ¡À» µÐ ij³ª´Ù ÀÇ·á±â±â ȸ»ç Ç÷μҴнº ¸ÞµðÄÃ(Flosonics Medical)Àº 1,400¸¸ ´Þ·¯ÀÇ ÀÚ±Ý Á¶´ÞÀ» ¿Ï·áÇß½À´Ï´Ù. ÀÌ º¸Á¶±ÝÀº ÁßÁõ ȯÀÚ °ü¸®¸¦ °³¼±Çϱâ À§ÇÑ ºñħ½ÀÀû ¹«¼± ¼¾¼ °³¹ß¿¡ »ç¿ëµÉ ¿¹Á¤ÀÔ´Ï´Ù. ¶ÇÇÑ GEÇコÄɾî´Â 2022³â 6¿ù ¹«¼± ȯÀÚ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀÎ Æ÷Æ®·¹ÀÌÆ® ¸ð¹ÙÀÏ(Portrait Mobile)À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ »õ·Î¿î ÀåÄ¡´Â ÀÓ»óÀÇ°¡ ȯÀÚÀÇ ¾Çȸ¦ Á¶±â¿¡ °¨ÁöÇÏ°í ÀÔ¿ø ȯÀÚÀÇ °Ç° »óŸ¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µ ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.
µû¶ó¼ À§ÀÇ »ç½ÇÀ» °í·ÁÇϸé, ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ÖƼ ÆĶó¹ÌÅÍ È¯ÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀº º»ÁúÀûÀ¸·Î ¼¼ºÐȵǾî ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϱâ À§ÇØ ÇÕº´, Àμö, Çù¾÷°ú °°Àº Àü·«Àû ¿òÁ÷ÀÓ¿¡ Âü¿©ÇÏ°í ÀÖ½À´Ï´Ù. Abbott Laboratories, Becton, Dickinson and Company, GE Healthcare, Medtronic PLC, Philips Healthcare¿Í °°Àº ÁÖ¿ä ½ÃÀå ±â¾÷µéÀÌ ½ÃÀå °æÀïÀ» °ÈÇÏ°í ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ °ø°ø ¹× ¹Î°£ Á¶Á÷ÀÇ Çõ½Å°ú ÅõÀÚ Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ¾÷°è °æÀïÀÌ Ä¡¿ÇØÁú °ÍÀÔ´Ï´Ù.
The Multi-Parameter Patient Monitoring Market size is estimated at USD 11.44 billion in 2024, and is expected to reach USD 16.40 billion by 2029, growing at a CAGR of 7.48% during the forecast period (2024-2029).
COVID-19 significantly impacted the multi-parameter patient monitoring market in the initial phases owing to the rise in COVID-19-affected patients with multiple comorbid conditions, including cardiac and neurologic complications. For instance, in an article published in March 2022 by PubMed, the study indicated that patient monitoring in Canada increased significantly due to the COVID-19 pandemic since there was a rise to alleviate the congestion in healthcare services. Furthermore, according to the article published in March 2021 in PubMed, researchers developed a vital-sign telemedicine system during the pandemic using internet infrastructure. Hence, multi-parameter patient monitoring was less hectic due to the advantages offered by telemedicine. Currently, the market is likely to witness growth in the multi-parameter patient monitoring market owing to the rise in chronic diseases, relaxed restrictions for medical device import and exports, and demand for patient monitoring and home-based devices. Hence the market is expected to have stable growth during the forecast period of the study.
Furthermore, the growth of the multi-parameter patient monitoring market is attributed to the rising burden of chronic diseases due to lifestyle changes, increased geriatric population, growing preference for home and remote monitoring, and the ease of use of portable devices. For instance, according to the estimations from IARC, the number of new cancer cases is likely to be 21,618,445 by 2025. The number will rise to 24,044,406 by 2030. Furthermore, as per the American Heart Association Heart and Stroke Statistics 2022 Update, the incidence of EMS-assessed non-traumatic out-of-hospital cardiac arrests (OHCA) in people of any age is estimated to be 356,461, or nearly 1,000 people each day. As per the same report, there are more than 356,000 out-of-hospital cardiac arrests (OHCA) annually in the U.S., almost 90% of them fatal. Hence, considering the high prevalence of chronic diseases, the demand for multi-parameter patient monitoring devices is likely to increase, thereby boosting market growth over the forecast period.
Patient monitoring technologies come into play and identify small changes in the patient's physiological data, promoting self-monitoring. As a result, it reduces readmissions and avoidable hospitalizations, as well as the number of unnecessary trips to the doctor's office and travel-related expenses. Patient monitoring technologies, when used correctly, can increase access to quality treatment while saving time and money. Other factors, such as government funding related to the research and development of chronic disease treatment, are anticipated to fuel the market's growth over the forecast period. For instance, as per the November 2021 update from the Government of Canada, in 2021, they invested USD 35 million in diabetes, specifically, USD 25 million for diabetes research, surveillance, and prevention and the development of a national framework for diabetes. It includes a recommitment to the Juvenile Diabetes Research Foundation (JDRF) and the Canadian Institutes of Health Research (CIHR) Partnership to Defeat Diabetes by investing up to USD 15 million to be matched by JDRF Canada and its donors for type 1 diabetes research.
Therefore, as the number of chronic disorders rises, the demand for the multi-parameter patient monitoring market is believed to grow over the forecast period. However, stringent regulatory frameworks and a lack of proper reimbursement are expected to hinder market growth.
Multi-parameter monitors are of two major types, portable and fixed. Portable monitors are anticipated to witness growth in the market over the forecast period owing to the ease of handling and convenience. Factors such as growing home healthcare, ease of monitoring post-surgical recovery patients, rising ambulatory care facilities, and increasing adoption of remote patient monitoring are driving the market growth. For instance, as per the article published in March 2021 by a Pakistan Journal of Science, the portable smart mini patient monitor prototype for enhanced healthcare results and patient-centered care captured and displayed critical physiological signals such as heartbeats, body temperature, ECG, and SPO2. The study depicted the combination of multiple sensors into a single portable device that produces various physiological signals at once with exact accuracy. People can conveniently record, save, and use it for medical diagnosis.
Additionally, competition among the major market players is rising owing to growing technological advancements. For instance, in February 2022, Singapore brand BUZUD, Fosun Trade Medical Device, launched two new medical devices. BUZUD Multi-Parameter Monitor (MPM) streamlines the medical monitoring process and helps healthcare professionals provide more patient care. The second one is BUZUD PulseBit EX, a personal electrocardiogram (ECG) tracker that makes heart care affordable and convenient for heart patients. Such launches will propel the growth of the market segment.
The rising awareness regarding healthcare and increasing concern for the constant monitoring of health parameters of patients, pre-and post-surgery, is expected to drive the growth of the portable multi-parameter monitors market.
North America will likely witness growth in the overall multi-parameter monitoring market over the forecast period. The multi-parameter patient monitoring market in the US is likely to see a significant market share in the North American region due to the high quality of the healthcare system and modern medical technology. Moreover, increased chronic disease and lifestyle changes immensely contributed to the market growth. For instance, according to the data published by the International Diabetes Federation (IDF) in 2021, the diabetes incidence in Canada (per 100,000) in 2021 was around 37.9% in children aged between 0-14 years. In addition, the number of adults aged 20-79 years suffering from diabetes in Canada was around 3 million for the year 2021. Therefore, with the increasing burden of diabetes in Canada, the multi-parameter monitoring market is expected to witness healthy growth over the forecast period.
In addition, key players are implementing strategic initiatives to gain a higher market share within the regional market. For instance, in July 2021, Abbott introduced Jot Dx, an insertable cardiac monitor. It can reduce data burden and diagnose abnormal heart rhythms. In February 2021, Flosonics Medical, a Canadian medical device company focused on non-invasive hemodynamic monitoring, closed funding of USD 14 million. The grant helps to develop non-invasive wireless sensors to improve the management of critically ill patients. Moreover, in June 2022, GE Healthcare launched its wireless patient monitoring system, Portrait Mobile. Its new device help clinicians detect early patient deterioration and constantly monitor patients' health during their stay at the hospital.
Hence, considering the above facts, North America is expected to witness growth over the forecast period.
The multi-parameter patient monitoring market is fragmented in nature. The key players are involved in strategic movements such as mergers, acquisitions, and collaborations to increase the market growth. Significant market players, such as Abbott Laboratories, Becton, Dickinson and Company, GE Healthcare, Medtronic PLC, and Philips Healthcare, are intensifying the market competition. Innovations and increasing investments from various public and private organizations will intensify industry rivalry worldwide.